Cost-effectiveness analysis of non-invasive vagus nerve stimulation for the treatment of chronic cluster headache.

ABSTRACT:

Background

Cluster headache (CH) is a debilitating condition that is generally associated with substantial health care costs. Few therapies are approved for abortive or prophylactic treatment. Results from the prospective, randomised, open-label PREVA study suggested that adjunctive treatment with a novel non-invasive vagus nerve stimulation (nVNS) device led to decreased attack frequency and abortive medication use in patients with chronic CH (cCH). Herein, we evaluate whether nVNS is cost-effective compared with the current standard of care (SoC) for cCH.

Methods

A pharmacoeconomic model from the German statutory health insurance perspective was developed to estimate the 1-year cost-effectiveness of nVNS + SoC (versus SoC alone) using data from PREVA. Short-term treatment

SUBMITTER: Morris J 

PROVIDER: S-EPMC4840129 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature